SMTL ID : 8or1.1

Co-crystal strucutre of PD-L1 with low molecular weight inhibitor

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 3.50 Å

Oligo State

homo-dimer

Ligands

1 x VYC: 5-[[5-[[2-chloranyl-3-(2-fluorophenyl)phenyl]methoxy]-2-[(~{E})-2-hydroxyethyliminomethyl]phenoxy]methyl]pyridine-3-carbonitrile(Non-covalent)

VYC.1: 17 residues within 4Å: Chain A: T.3, M.98, I.99, S.100, A.104, D.105, Y.106, K.107, R.108 Chain B: I.37, Y.39, Q.49, M.98, I.99, S.100, A.104, D.105 8 PLIP interactions: 4 interactions with chain B, 4 interactions with chain A Hydrophobic interactions: B:Y.39, B:M.98, B:A.104, A:Y.106 Halogen bonds: B:D.105 Hydrogen bonds: A:K.107, A:R.108, A:R.108

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Zhang, H. et al., Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2'-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors. J.Med.Chem. (2023)

Release Date

2023-08-02

Peptides

Programmed cell death 1 ligand 1: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

Programmed cell death 1 ligand 1